Clasp iid one-year data confirm safety and efficacy of edwards pascal system for degenerative mitral regurgitation

San francisco , oct. 26, 2023 /prnewswire/ -- edwards lifesciences corporation (nyse: ew) announced one-year results from clasp iid, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (teer) therapies, as well as one-year results from the clasp iid registry. the studies confirm the clinical and quality-of-life benefits of mitral regurgitation (mr) reduction with the pascal system in a broad population of patients with degenerative mitral regurgitation (dmr).
EW Ratings Summary
EW Quant Ranking